PLOS ONE:肿瘤微环境如何促进乳腺癌细胞迁移

2018-04-01 海北 MedSci原创

肿瘤微环境(TME)可以促进肿瘤细胞的侵袭和转移。促癌微环境转化的一个重要步骤是正常基质成纤维细胞向癌相关成纤维细胞(CAF)的转化。

肿瘤微环境(TME)可以促进肿瘤细胞的侵袭和转移。促癌微环境转化的一个重要步骤是正常基质成纤维细胞向癌相关成纤维细胞(CAF)的转化。CAF存在于大多数实体瘤中,并且可以分泌细胞因子,趋化因子和生长因子到TME中,直接促进肿瘤细胞的转移。 但至今为止,TME对移动性肿瘤细胞中细胞骨架调节的确切作用仍然是个谜。

保守的formin细胞骨架调节蛋白家族在非分支肌动蛋白丝的装配和/或捆绑中起着重要的作用。哺乳动物的mDia2 / DIAPH3 / Drf3 / Dia可以组装成为一个动态的F-肌动蛋白细胞骨架,它是肿瘤细胞迁移和侵袭的基础。

因此,来自托莱多大学健康科学院的研究人员试图了解CAF衍生的趋化因子是否通过修饰由formin组装的F-肌动蛋白细胞骨架,进而影响乳腺肿瘤细胞的运动性。

MDA-MB-231细胞中,相对于正常人类乳房成纤维细胞(HMF)的条件培养基(CM),来自WS19T CAF(人乳房肿瘤相邻CAF系)的条件培养基能够显着并强烈增加伤口闭合和细胞侵袭性。与对照HMF-CMWS21T CAF-CM(该乳腺CAF细胞系未能促进稳健的MDA-MB-231迁移)相比,WS19T-CM还促进了MDA-MB-231细胞中蛋白酶体介导的mDia2降解。

相对于对照WS21T CM,细胞因子阵列分析鉴定了WS19T CM中上调的分泌因子。研究人员将CXCL12鉴定为影响mDia2蛋白丢失的CM因子,这增加了MDA-MB-231细胞的迁移。

这些数据表明,CAF通过CXCL12的分泌,以调节乳腺肿瘤细胞中mDia2-定向的细胞骨架的机制,促进肿瘤细胞的迁移和侵袭。


原始出处:

Kaitlyn M. Dvorak et al. Carcinoma associated fibroblasts (CAFs) promote breast cancer motility by suppressing mammalian Diaphanous-related formin-2 (mDia2). PLOS ONE, 2018; DOI: 10.1371/journal.pone.0195278


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1790134, encodeId=c81d1e90134cb, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Apr 26 02:45:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640937, encodeId=2f29164093e21, content=<a href='/topic/show?id=7c99939e3fd' target=_blank style='color:#2F92EE;'>#迁移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93973, encryptionId=7c99939e3fd, topicName=迁移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 06 09:45:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252484, encodeId=71b41252484f6, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Apr 03 06:45:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529585, encodeId=78a1152958531, content=<a href='/topic/show?id=6264e80409d' target=_blank style='color:#2F92EE;'>#细胞迁移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78040, encryptionId=6264e80409d, topicName=细胞迁移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d5e11955593, createdName=amy0554, createdTime=Tue Apr 03 06:45:00 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1790134, encodeId=c81d1e90134cb, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Apr 26 02:45:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640937, encodeId=2f29164093e21, content=<a href='/topic/show?id=7c99939e3fd' target=_blank style='color:#2F92EE;'>#迁移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93973, encryptionId=7c99939e3fd, topicName=迁移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 06 09:45:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252484, encodeId=71b41252484f6, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Apr 03 06:45:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529585, encodeId=78a1152958531, content=<a href='/topic/show?id=6264e80409d' target=_blank style='color:#2F92EE;'>#细胞迁移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78040, encryptionId=6264e80409d, topicName=细胞迁移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d5e11955593, createdName=amy0554, createdTime=Tue Apr 03 06:45:00 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-08-06 hb2008ye
  3. [GetPortalCommentsPageByObjectIdResponse(id=1790134, encodeId=c81d1e90134cb, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Apr 26 02:45:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640937, encodeId=2f29164093e21, content=<a href='/topic/show?id=7c99939e3fd' target=_blank style='color:#2F92EE;'>#迁移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93973, encryptionId=7c99939e3fd, topicName=迁移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 06 09:45:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252484, encodeId=71b41252484f6, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Apr 03 06:45:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529585, encodeId=78a1152958531, content=<a href='/topic/show?id=6264e80409d' target=_blank style='color:#2F92EE;'>#细胞迁移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78040, encryptionId=6264e80409d, topicName=细胞迁移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d5e11955593, createdName=amy0554, createdTime=Tue Apr 03 06:45:00 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-04-03 yxch36
  4. [GetPortalCommentsPageByObjectIdResponse(id=1790134, encodeId=c81d1e90134cb, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Apr 26 02:45:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640937, encodeId=2f29164093e21, content=<a href='/topic/show?id=7c99939e3fd' target=_blank style='color:#2F92EE;'>#迁移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93973, encryptionId=7c99939e3fd, topicName=迁移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 06 09:45:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252484, encodeId=71b41252484f6, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Apr 03 06:45:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529585, encodeId=78a1152958531, content=<a href='/topic/show?id=6264e80409d' target=_blank style='color:#2F92EE;'>#细胞迁移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78040, encryptionId=6264e80409d, topicName=细胞迁移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d5e11955593, createdName=amy0554, createdTime=Tue Apr 03 06:45:00 CST 2018, time=2018-04-03, status=1, ipAttribution=)]

相关资讯

NCCN临床实践指南:乳腺癌(2018.V1)

2018年3月,美国国家综合癌症网络(NCCN)发布了乳腺癌管理指南2018年第1版,指南主要内容涉及: 指南更新摘要 非浸润性乳腺癌 浸润性乳腺癌 特殊考虑

JCO:同为乳腺癌患者,男女各有不同

男性乳腺癌约占所有乳腺癌新病例的1%,其分子生物学特征、治疗与结局的数据非常有限,人们对其了解主要来自乳腺癌女性的数据推断。

J Clin Oncol:来曲唑治疗延长至10年 乳腺癌症的患者生活质量有无影响?

内分泌治疗是晚期乳腺癌治疗的重要手段之一,来曲唑是毒性作用较低的第三代芳香化酶抑制剂。2018年2月,发表于《J Clin Oncol》上的一项随机试验,考察了将来曲唑辅助治疗延长至10年,是否与激素受体阳性乳腺癌患者生活质量(QOL)恶化相关。

EBCC-11︱术前系统治疗反应良好的乳腺癌患者的局部治疗

在第11届欧洲乳腺癌大会(EBCC-11)第三天上午的临床科学论坛中,来自英国、荷兰、西班牙和奥地利等国的六位教授对新辅助治疗反应良好的患者后续局部治疗的处理策略进行了专题讨论。内容涵盖反应良好的病理判定、标记物的放置和评估、后续能否减少局部放射和手术治疗等热点问题。

Breast Cancer Res Treat:三阴性乳腺癌突变与复发率无关

编者按:由于三阴性乳腺癌的雌激素受体、孕激素受体、人类表皮生长因子受体2(HER2)均为阴性,目前缺乏有效靶向疗法,其全身治疗主要依靠化疗,而且复发率较高。无数科学家正在焚膏继晷夜以继日地探索各种通路基因突变,寻找有效靶点。那么,现有已知基因突变,能否预测三阴性乳腺癌的化疗效果和复发率?

密歇根州立大学:一种靶向药物,可预防乳腺癌和肺癌

密歇根州立大学的Liby博士和Jamie Bernard博士基于发表在《癌症预防研究》杂志上的两项研究测试了一种药物,可以预防与肥胖相关的基因引发的乳腺癌和肺癌,并阻止这些癌症的生长。